Symposium  /  April 15, 2024  -  April 16, 2024

Symposium on „Validating DIGItal biomarkers for better personalized treatment of Parkinson’s Disease“


Parkinson's Disease (PD) is a neurodegenerative disorder that affects 7-10 million patients worldwide. Patients suffer from symptoms including tremors, gait and speech impairments, and deterioration of cognitive performance. The severity of these symptoms varies greatly from individual to individual, and existing medications can neither cure nor stop the progression of the disease.

The DIGIPD project evaluates the added value of modern digital technologies, in particular the digital recording of gait and speech disorders and the detection of changes in facial expressions, as well as the added value compared to the classic, questionnaire-based recording of symptoms.

The project also includes an analysis of the legal and ethical situation in handling sensitive patient data.

Purpose of the symposium

  • Overview of the DIGIPD project
  • Understanding digital readouts (DR)
  • Discussion on clinical benefits of digital readouts
  • Provide a walkthrough on the legal and ethical aspects of AI
  • Demonstrate the impact of the use of digital technology and AI on patients and society in routine clinical practice
  • A community effort: discussion on lessons learned and future perspectives
Aims impact
  • Evaluate DR with respect to:
    • Discrimination against healthy controls
    • Disease monitoring and prognosis
    • Validity and interpretation
  • Understand ethical, legal, and social implications
  • DR for AI-based patient stratification
    • better individualized disease treatment
    • Optimizing clinical trial design
    • Understanding the relationship between established measures
  • Understanding of patient‘s views on AI and DR


Project overview


  • Fraunhofer SCAI
  • University Medical Center Erlangen
  • ICM
  • Télécom Sud Paris
  • University of Namur
  • Portabiles HealthCare Technologies
  • Association Parkinson Madrid